The study showed both hippocampal atrophy and neocortical tauopathy are independent predictors of lower cognition, mediating the effects of initial entorhinal tau and Aβ pathology.
About 45% of the variance in cognitive decline was explained by combining the change measures in the different imaging biomarkers.
The results suggest that measuring longitudinal changes in hippocampal volume as a secondary outcome in clinical trials, in addition to Aβ and tau pathologies, may help predict individual trajectories of cognitive decline and response, or lack of response, to AD drugs, write the authors.
[
add
]
[
|
|
...
]